|Bid||0.00 x 1200|
|Ask||0.00 x 1200|
|Day's Range||99.10 - 106.04|
|52 Week Range||20.72 - 115.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Moderna (MRNA) signs a deal to supply up to 160 million vaccine doses to European Commission The vaccine is under review in Europe.
Moderna popped Wednesday after the company inked a deal for at least 80 million doses of its coronavirus vaccine with the European Commission. The drug is based on messenger RNA technology.
The biotech firm will go from no product sales to more than $13 billion next year, writes Goldman Sachs’ Salveen Richter. She’s raising her price target for the stock to $139 from $107.